FDA Priority Review for Post-Neoadjuvant T-DXd in HER2+ Early BC
Episode Summary
The FDA granted Priority Review to trastuzumab deruxtecan for high-risk HER2-positive early breast cancer with residual disease, signaling a potential new standard to reduce recurrence risk.